$APLT
Applied Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122804 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $122.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.04M
YoY Change 219.26%
% of Gross Profit
Research & Development $14.83M
YoY Change 37.49%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $29.87M
YoY Change 92.74%
Operating Profit -$29.74M
YoY Change 91.95%
Interest Expense $1.357M
YoY Change 246.17%
% of Operating Profit
Other Income/Expense, Net -$38.85M
YoY Change 44.55%
Pretax Income -$68.59M
YoY Change 61.89%
Income Tax
% Of Pretax Income
Net Earnings -$68.59M
YoY Change 61.89%
Net Earnings / Revenue -56222.13%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.48
COMMON SHARES
Basic Shares Outstanding 116.4M 114.8M
Diluted Shares Outstanding 144.3M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.12M
YoY Change 164.32%
Cash & Equivalents $98.90M
Short-Term Investments $253.0K
Other Short-Term Assets $366.0K
YoY Change -56.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $104.6M
YoY Change 135.13%
LONG-TERM ASSETS
Property, Plant & Equipment $1.963M
YoY Change 292.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.963M
YoY Change 177.65%
TOTAL ASSETS
Total Short-Term Assets $104.6M
Total Long-Term Assets $1.963M
Total Assets $106.6M
YoY Change 135.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.837M
YoY Change -52.76%
Accrued Expenses $12.98M
YoY Change 2.21%
Deferred Revenue $212.0K
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $98.97M
YoY Change 78.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.707M
YoY Change 143.86%
Total Long-Term Liabilities $1.707M
YoY Change 132.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.97M
Total Long-Term Liabilities $1.707M
Total Liabilities $100.7M
YoY Change 79.01%
SHAREHOLDERS EQUITY
Retained Earnings -$618.2M
YoY Change 43.47%
Common Stock $11.00K
YoY Change 57.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.892M
YoY Change
Total Liabilities & Shareholders Equity $106.6M
YoY Change 135.79%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$68.59M
YoY Change 61.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$23.33M
YoY Change 58.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -23.33M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -23.33M
YoY Change -1367.93%
FREE CASH FLOW
Cash From Operating Activities -$23.33M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4710000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34683000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15585000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
29865000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
15495000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001697532
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38898
dei Entity Registrant Name
EntityRegistrantName
Applied Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3405262
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-9226
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
APLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
116356474
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98867000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49898000
CY2024Q3 aplt Security Deposit And Leasehold Improvements Current
SecurityDepositAndLeaseholdImprovementsCurrent
253000
CY2023Q4 aplt Security Deposit And Leasehold Improvements Current
SecurityDepositAndLeaseholdImprovementsCurrent
254000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5483000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4234000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
104603000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
54386000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1963000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
447000
CY2024Q3 us-gaap Assets
Assets
106566000
CY2023Q4 us-gaap Assets
Assets
54833000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
264000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
429000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2837000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1742000
CY2024Q3 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13489000
CY2023Q4 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15286000
CY2024Q3 aplt Warrant Liability Current
WarrantLiabilityCurrent
82377000
CY2023Q4 aplt Warrant Liability Current
WarrantLiabilityCurrent
53725000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
98967000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71182000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1707000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38000
CY2023Q4 aplt Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
759000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1707000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
797000
CY2024Q3 us-gaap Liabilities
Liabilities
100674000
CY2023Q4 us-gaap Liabilities
Liabilities
71979000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116356474
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116356474
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84869832
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84869832
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
624098000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
451432000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-618217000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-468586000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5892000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-17146000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106566000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54833000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
455000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10660000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14828000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10785000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37049000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38602000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15037000
us-gaap Operating Expenses
OperatingExpenses
71732000
us-gaap Operating Expenses
OperatingExpenses
54187000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29743000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15495000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71277000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43527000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1357000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
392000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2572000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1020000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
40184000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
27277000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
80845000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39611000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-81000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38848000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26875000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78354000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38557000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-68591000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
us-gaap Net Income Loss
NetIncomeLoss
-149631000
us-gaap Net Income Loss
NetIncomeLoss
-82084000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144345781
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144345781
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90669969
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90669969
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137893249
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
137893249
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75482234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75482234
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-68591000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
us-gaap Net Income Loss
NetIncomeLoss
-149631000
us-gaap Net Income Loss
NetIncomeLoss
-82084000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-51000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-51000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68591000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42370000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-149631000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82135000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4061000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2055000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10137000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-51000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4072000
CY2023Q2 aplt Stock Issuance Costs
StockIssuanceCosts
2500000
CY2023Q2 aplt Stock And Warrants Issued During Period Value Common Stock And Pre Funded Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
27450000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1843000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29577000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4334000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7004000
CY2023Q3 aplt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
26755000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1836000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11044000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-17146000
CY2024Q1 aplt Stock Issuance Costs
StockIssuanceCosts
8200000
CY2024Q1 aplt Stock And Warrants Issued During Period Value Common Stock And Pre Funded Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndPreFundedWarrants
104748000
CY2024Q1 aplt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
61218000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2379000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-83938000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
67294000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
310000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1890000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
2898000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
72392000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2091000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-68591000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5892000
us-gaap Profit Loss
ProfitLoss
-149631000
us-gaap Profit Loss
ProfitLoss
-82084000
us-gaap Share Based Compensation
ShareBasedCompensation
6360000
us-gaap Share Based Compensation
ShareBasedCompensation
5734000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
566000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
1723000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
345000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
347000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-357000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-356000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
80845000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39611000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
1546000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1815000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
480000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1095000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1471000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-1486000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-2816000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-759000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
227000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64836000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38168000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4944000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8928000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13872000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
104748000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
34606000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
1546000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
311000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1393000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9025000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10250000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
343000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113805000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45096000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48969000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20800000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49898000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16657000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98867000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37457000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
52193000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
16505000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1861000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-51000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
152000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants And Exercise Of Warrants Net
ProceedsFromIssuanceOfSharesAndPreFundedWarrantsAndExerciseOfWarrantsNet
113800000
us-gaap Profit Loss
ProfitLoss
-149600000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-618200000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98900000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. In preparing the financial statements, management used significant estimates in the following areas, among others: prepaid and accrued expenses; warrant liabilities valuation; license revenue; research and development services revenue; stock-based compensation expense; the likelihood of realization of deferred tax assets; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results could differ from those estimates.</span></p>
CY2024Q3 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2885000
CY2023Q4 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2880000
CY2023Q4 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
566000
CY2024Q3 aplt Prepaid Manufacturing Costs
PrepaidManufacturingCosts
327000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
768000
CY2024Q3 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
875000
CY2023Q4 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
284000
CY2024Q3 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
262000
CY2023Q4 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
262000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
366000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
242000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5483000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4234000
CY2024Q3 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
4386000
CY2023Q4 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
10142000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
310000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
212000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
667000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1166000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1307000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2013000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2066000
CY2024Q3 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
3770000
CY2023Q4 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
19000
CY2024Q3 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
1382000
CY2023Q4 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
396000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
560000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
379000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13489000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15286000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2091000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1836000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6360000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5734000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
700000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3700000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4695619
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7875000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
327492
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
58123
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.05
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4310004
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27613000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4168686
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26561000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
141318
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.05
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P7Y2M12D
CY2024Q3 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue
1052000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2024Q3 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Vested Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedGrantDateFairValue
100000
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Vested Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedGrantDateFairValue
200000
CY2023Q3 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Vested Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedGrantDateFairValue
100000
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Vested Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedGrantDateFairValue
400000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
132000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
us-gaap Operating Lease Cost
OperatingLeaseCost
386000
us-gaap Operating Lease Cost
OperatingLeaseCost
378000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1545
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
135000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
546000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
556000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
550000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
563000
CY2024Q3 aplt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
479000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2829000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
858000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1971000
CY2024Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-68591000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
us-gaap Net Income Loss
NetIncomeLoss
-149631000
us-gaap Net Income Loss
NetIncomeLoss
-82084000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144345781
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144345781
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90669969
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90669969
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137893249
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
137893249
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75482234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75482234
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122804-index-headers.html Edgar Link pending
0000950170-24-122804-index.html Edgar Link pending
0000950170-24-122804.txt Edgar Link pending
0000950170-24-122804-xbrl.zip Edgar Link pending
aplt-20240930.htm Edgar Link pending
aplt-20240930.xsd Edgar Link pending
aplt-ex31_1.htm Edgar Link pending
aplt-ex31_2.htm Edgar Link pending
aplt-ex32_1.htm Edgar Link pending
aplt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
aplt-20240930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending